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Background
Bisphosphonates selectively inactivate osteoclasts. In some 
situations they can do this while osteoblast activity is main-
tained. This leads to increased net bone formation.
Bisphosphonates are powerful drugs. Their ability to reduce 
the  risk  of  osteoporotic  fractures  has  saved  thousands  of 
people from becoming a fracture patient. Osteoporosis is due 
to an imbalance in the maintenance remodeling of the skel-
eton. This remodeling is different from the repair processes 
following fracture or bone surgery. Because research on the 
use of bisphosphonates has mostly focused on osteoporosis, 
their effects on repair processes have long been overlooked. 
In bone remodeling, osteoclasts and osteoblasts work closely 
together—also in a spatial sense—at defined remodeling sites. 
Their activities are coupled: a decrease in bone resorption due 
to bisphosphonates leads to a reduction in bone formation to a 
similar degree. Thus, it was long thought that bisphosphonates 
would only slow down bone repair. However, in bone repair, 
osteoblasts can work independently. This is clear if you just 
look at it in the microscope, where you can see large areas of 
undisturbed bone formation, separate from areas undergoing 
resorption and remodeling (Figure 1). A reduction in osteo-
clast activity can therefore be expected to shift the balance 
between formation and resorption towards increased net bone 
formation. During bone repair, bisphosphonates have an anti-
catabolic, or net anabolic, effect (Figure 2) (Little et al. 2005, 
Wermelin et al. 2007).
Bisphosphonates bind to bone mineral and are taken up by 
osteoclasts when the latter resorb bone, which inactivates the 
cell. This mechanism makes bisphosphonates highly osteo-
clast-specific; free bisphosphonate is quickly excreted via the 
kidneys. However, some macrophages may be affected, and 
there is in vitro evidence (Garcia-Moreno et al. 1998, Giuliani 
et al. 1998) that osteoblasts are stimulated by concentrations 
of bisphosphonates that are unlikely to occur in vivo (Schin-
deler and Little 2005).
It has been suggested that bisphosphonates may impair frac-
ture healing. Osteoporotic fractures indicate an increased risk 
of new fractures, and should be an incentive to start prophylac-
tic bisphosphonate treatment. Now, if bisphosphonates impair 
fracture healing, it would be wise to delay the start of second-
ary prevention until the fracture is healed. In animal experi-
ments, bisphosphonates increase fracture callus size and delay 
the regression in size after the fracture has healed (Madsen et 
al. 1998, Cao et al. 2002). No mechanical impairment had been 
demonstrated. In large clinical series, no increase in healing 
complications has been reported (Lyles et al. 2007). It would 
therefore seem free of risk to start bisphosphonates directly 
after the first osteoporotic fracture. However, if intravenous 
bisphosphonates are used, there is a risk that the affinity of 
the fracture site for bisphosphonates would be so large that 
the rest of the skeleton would not be reached by a sufficient 
amount, and remain untreated (Lyles et al. 2007). 
Figure 1. Biopsy from distal radial fracture 19 days after injury. An old, 
partly necrotic trabecula and woven bone forming without cartilage 
precursor within the marrow space.120  Acta Orthopaedica 2009; 80 (1): 119–123
The aim of this article is to discuss bisphosphonates together 
with  implants  in  bone.  I  therefore  now  leave  osteoporosis 
treatment. 
Fracture fixation devices
Systemic  bisphosphonate  treatment  can  increase  screw 
removal resistance. Screws can also be better fixated in bone 
if they are coated with bisphosphonates.
Plates and marrow nails have low friction to the bone, and 
transfer forces via large surfaces that lie on to bone and take 
up compressive forces. Their function is entirely due to gross 
shape. Screws are different: unlike nails, their conformation 
allows them to take up forces in all directions, except in rota-
tion around their axis. Complex fractures need screws. The 
strength of screw fixation depends on the strength of the bone 
close to the threads. For pull-out forces, this bone acts as a 
screw nut. In cortical bone, this screw nut is threaded at inser-
tion, and can have considerable strength. This may decrease 
with time, as the cortical bone is likely to resorb in response to 
the trauma (Dhert et al. 1998). In cancellous and osteoporotic 
bone, however, trabeculae might fracture at a distance from 
the drill or screw thread, making the “screw nut” even weaker 
than the intact cancellous bone would suggest. On the other 
hand, cancellous bone has a remarkable capacity to regenerate 
and will start making new bone at the traumatized site, and 
eventually form a bone shell around the screw. So whereas 
screw fixation in cortical bone is strong, with a risk of slight 
decrease over time, cancellous bone is weak with a tendency 
to gradual improvement. Unfortunately, there is often no time 
to wait for such improvement. 
Most patients are old, and unlike the young, they have little 
time. Our common fracture patients need to come back to load 
bearing quickly. If this does not lead to immediate mechani-
cal failure of the fracture fixation, there is risk of microinsta-
bility, leading to bone resorption around the screws (Ganz et 
al. 1975) (Figure 3) or accumulated damage leading to col-
lapse later on. There will be a race between these destructive 
processes and the repair response initiated by screw insertion 
trauma (and the fracture). Any therapy that would favor bone 
formation and inhibit bone loss around the screw would buy 
time and increase the chance that the fixation construct would 
last until the fracture is healed. This is where bisphosphonates 
come in.
In  one  randomized  clinical  study,  hydroxyapatite-coated 
external  fixation  pins  showed  a  higher  removal  torque  in 
patients given a bisphophonate systemically (Moroni et al. 
2007). In another randomized study, the same was found for 
metal pins—but not when they were coated with hydroxyap-
atite (Tägil et al. 2008). For local treatment, and possibly a 
stronger effect, bisphophonates can be injected directly into 
the screw hole. This has resulted in improved screw fixation 
in rats (Skoglund et al. 2004), but in clinical situations the 
bisphosphonate solution is likely to be flushed away by bleed-
ing and the treatment would be difficult to control. This prob-
Figure 2. Bone resorption and formation are coupled during remodeling, but not during the response to trauma.
Figure 3. The observation that microinstability of a screw may lead to 
resorption and gross loosening may explain the role of local fluid flow 
in bone resorption. Forces and hydrostatic pressure around a microun-
stable screw are not greater than around a fixed one, but local fluid 
flows are. Drawn from memory of a drawing by Perren.Acta Orthopaedica 2009; 80 (1): 119–123  121
lem could be overcome by specific devices such as a bisphos-
phonate-soaked foam plug inserted in the screw hole followed 
by an expander, which squeezes the solution out of the foam 
into the surrounding bone. Although feasible, this would be 
less practical than simply putting the bisphosphonate directly 
on the screw surface. This can be done by several techniques, 
which have been evaluated in animal experiments. 
Most experiments use calcium phosphate coatings (often 
hydroxyapatite) as a base (Peter et al. 2005, 2006). The test 
implants are more often rods than screws. They just need to 
be placed in a bisphosphonate solution and the affinity will 
adsorb the bisphosphonate to the calcium phosphate. Several 
groups have shown improved fixation with such treatments. 
One of them reported a risk of overdosing with amounts of 
bisphosphonate on the surface that are too high (Peter et al. 
2005). However, the number of animals was small, and these 
overdose effects were not reproduced in a similar experiment 
with more precise evaluation (Peter et al. 2006). Others have 
used a polylactic-glycolic acid polymer for slow release of the 
bisphosphonate (Greiner et al. 2007).
The group of Pentti Tengvall and myself has used a cross-
linked fibrinogen layer, covalently linked to metals via silanes. 
The crosslinked fibrinogen can bind several bisphosphonates 
chemically (Tengvall et al. 2004). This fibrinogen coating can 
be produced by simple chemical methods and can be steril-
ized by radiation (Wermelin et al. 2008b). Although fibrino-
gen is a protein, the crosslinking is so tight that it is more 
to be regarded as a polymer. The bisphosphonate appears to 
be released over a period of hours or days and the fibrinogen 
is degraded in a matter of weeks. The effects we have seen 
in a rat model are extraordinary. The pullout force for stain-
less steel screws was increased compared to controls after 2 
weeks. More remarkably, however, this difference increased 
continuously over time, so that the pullout force was doubled 
after 8 weeks. Histology showed that a shell of new bone had 
formed around the screw, inside the marrow cavity—some-
thing that was not seen in the controls (Wermelin et al. 2008a, 
b). This does not mean that bisphosphonates induce new bone 
formation like, for example, a BMP. The explanation appears 
to be that very scant, patchy loose bone or osteoid formed also 
around the control screws after 1 week, but then disappeared 
when resorption was not suppressed. When protected by the 
bisphosphonate, this early, scant bone served as a scaffold for 
continued bone growth, leading to the formation of a bony 
shell. 
Joint replacements
The initial stability of joint replacements can be improved 
both by systemic and local bisphosphonates.
The initial fixation of joint prostheses appears to be crucial for 
long-term success (Kärrholm et al. 1994, Ryd et al. 1995). The 
surfaces of joint replacements are mostly adjacent to cancel-
lous bone. There is often a gradual change in position of the 
prosthesis during the first weeks, which can be explained by 
microfracturing, until the prosthesis has settled into a position 
in which the load is evenly distributed to the bone. This is 
not the only explanation, however. By use of radiostereom-
etry, we have shown that both systemically and locally applied 
bisphosphonates reduce this early migration (Hilding et al. 
2000, Hilding and Aspenberg 2006, 2007). This means that 
osteoclasts  are  involved.  The  bisphosphonates  may  inhibit 
resorption of the bone next to the prosthesis, which can be 
nothing but necrotic and prone to resorption. Another possi-
bility is that the response to the trauma gets a more positive 
balance between bone formation and resorption, as previously 
described for screws. The first study used a rather high dose of 
clodronate given systemically, starting 3 weeks before surgery 
(Hilding et al. 2000). The second used ibandronate applied 
locally to the cut bone surface immediately before cementa-
tion (Hilding and Aspenberg 2007). 
A third knee study failed to show any effect of a bisphos-
phonate upon radiostereometric migration. In contrast to the 
other  2  studies,  this  study  used  an  uncemented  prosthesis 
and  a  conventional  osteoporosis-based  dose  of  alendronate 
taken orally (Hansson et al. 2009). The reason that it did not 
work may be that uncemented prostheses migrate much more 
than cemented ones. This probably represents settling due to 
unevenness of the cut bone surfaces. At first, only small can-
cellous areas have to take all the load, and they are likely to be 
compacted. Any effect upon resorption might be hidden in the 
variation associated with this larger migration. Another pos-
sibility might be that the dose of alendronate was too low.
The early migration of hip prostheses can be reduced by 
bisphosphonates. In a randomized double-blind study, a single 
infusion of zoledronate abolished the migration of the cup and 
improved the Harris hip score (Friedl et al. 2009). The study 
used a less precise method than RSA, and another similar study 
showed no effect (Wilkinson et al. 2005). It has recently been 
shown that zoledronate given as a single intravenous infusion 
after hip surgery will to a great extent be concentrated to the 
traumatized bone region, so that local treatment may not be 
necessary to achieve a high local dose (Amanat et al. 2007).
The  2  positive  knee  studies  both  showed  a  reduction  in 
“maximal total point motion” from about 0.4 to 0.3 mm at 1 
year. How can this small difference be of any clinical impor-
tance? There are three reasons to believe this. First, migra-
tion is associated with microinstability, which indicates that 
there is a fibrous membrane between the implant and the bone 
(Hilding et al. 1995). This membrane allows generation of 
local fluid flow and gives access to particulate debris, both 
of which are known to induce bone resorption and thereby 
loosening. 
Secondly, there has been a study on 155 knee prostheses 
of  various  types,  which  were  included  in  different  studies 
and then analyzed retrospectively when 12 of them had been 122  Acta Orthopaedica 2009; 80 (1): 119–123
revised for loosening (Ryd et al. 1995). It turned out that those 
that  loosened  had  migrated  statistically  significantly  more 
already at 6 months. The highest predictive power was found 
for migration during the second year. This study investigated 
patients who were operated in the 1980s, however, when the 
quality of implants and surgery was still developing. Both the 
failure rate and the migration were higher than in later years. 
The study would probably be impossible to repeat, because 
the low failure rate with modern methods would necessitate 
an impossibly high number of patients to achieve a reasonable 
statistical power. 
A third reason to believe that early migration is ominous 
would be if there is a dichotomy between stable and migrat-
ing prostheses (or between almost stable prostheses and those 
with more migration). We have recently shown that such a 
dichotomy exists for cemented acetabular cups (Aspenberg 
et al. 2008). Most cups did not migrate at all: their radioste-
reometric values apparently represented signal noise. Some 
cups, however, showed true migration. Preliminary data from 
my group indicate that there is a similar dichotomy for both 
cemented  and  uncemented  tibial  components  (unpublished 
observations). This indicates that the small reduction in mean 
value induced by the bisphosphonates (0.3 mm as opposed to 
0.4 mm) in reality represents a large reduction in the number 
of migrating implants. If we believe that lack of stable fixation 
puts the patient at risk of loosening, bisphosphonate treatment 
would be a good idea. 
Several studies have shown that bisphosphonates can pre-
vent the loss in bone density normally seen at some distance 
from prostheses by DXA, especially bone loss due to “stress 
shielding”. Although a striking effect, it is uncertain whether 
this has any relevance for prosthetic fixation (Bhandari et al. 
2005).
Can bisphosphonates be used to stop the progress of symp-
tomatic loosening? Attempts to show this in a large random-
ized study have, to my knowledge, failed and remained unpub-
lished. We have also tried local injection of bisphosphonates 
into  the  pseudojoint.  Because  this  communicates  with  the 
space around the loose prosthesis (the “effective joint space”), 
we hoped to expose the periprosthetic bone to a higher con-
centration. In a few pilot cases, this did not seem to have any 
effect. We therefore injected a radioactive technetium-labeled 
bisphosphonate  and  could  see  on  a  scintimetric  tomogram 
that the bisphosphonate was taken up by the general circula-
tion from the loosening membrane before reaching the bone 
(unpublished observations). 
The apparent lack of an effect of systemic treatment for 
blocking progress of loosening can be explained by the fact 
that  bisphosphonates  never  inhibit  resorption  completely; 
osteoclasts must resorb some bone in order to be intoxicated 
by the bisphosphonate. If the resorptive stimulus is strong, 
and the number of recruited osteoclasts is high, the bone will 
be  resorbed  anyway  (Åstrand  and Aspenberg  2002).  How-
ever, drugs that block the RANKL signaling system, such as 
osteoprotegerin or monoclonal antibodies to RANK, may be 
more potent for this indication because they inhibit osteoclast 
recruitment instead of reducing their activity. This might lead 
to complete inhibition of resorption.
Dental implants
Dental implants need time to osseointegrate before loading. 
This time might be reduced by local bisphosphonate treat-
ment.
Dental implants are screws inserted in the jawbones. Nor-
mally, they are left unloaded after insertion, hidden under the 
gingiva. Months later, when they have osseointegrated, they 
are re-exposed and tooth replacements are attached to them. 
As  bisphosphonates  accelerate  mechanical  fixation  under 
other clinical and experimental conditions, they might shorten 
the waiting time until loading of dental implants. We have 
made a pilot study in which 5 edentolous patients received 
7 dental implants each, 1 of which was coated with bisphos-
phonates. Stability of fixation was estimated by measuring 
vibration resonance frequency. In all 5 patients, the bisphos-
phonate-coated implants showed the greatest improvement in 
resonance frequency (unpublished observations). This study 
was not randomized or blinded, and there are feasible expla-
nations for the findings other than that of a bisphosphonate 
effect. Still, the results suggest that it may be worthwhile to 
study whether bisphosphonate-coated implants can reduce the 
time until loading for dental implants. It is a problem, how-
ever, that the condition known as “osteonecrosis of the jaw” 
has caused fear of using bisphosphonates in conjunction with 
oral surgery. This condition is not really an osteonecrosis, but 
an osteomyelitis, in which bisphosphonate-containing bone 
probably  cannot  be  resorbed  fast  enough  for  the  lesion  to 
heal (Aspenberg 2006, Dodson et al. 2008). At coated dental 
implants only the bone adjacent to the implant would contain 
bisphosphonate, and it could easily be removed together with 
the implant, if needed. 
Conclusion 
Although antiresorptive, bisphosphonates may paradoxically 
increase the amount of bone adjacent to an implant, leading to 
better fixation. This has already been shown in several clinical 
studies, but awaits further evaluation. 
The author has shares in a company involved in developing implant coatings 
for release of bisphosphonates and other drugs.
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